N/A N=10 Effectiveness of rTMS on Pain and Quality of Life in Patients With Cancer Neuropathic Pain. Clinical Trial.
Neuropathic Pain
Primary: Effect of Change of 20 rTMS Sessions on Pain — 5.53; 1.60; 1.97; 3.48 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=37 EMPOWER: Empowering the Management of Pain-Obesity-Weight Through Enhanced Reward
Low Back Pain
Primary: Session-level Engagement (NOTE: This is a Pilot Study and There is Not a True Primary Outcome. There Are Several Descriptive Outcomes That Will Inform Our Decision to…
N/A N=531 Implementing Pharmacogenetic Testing in Gastrointestinal Cancers
Gastrointestinal Cancer
Primary: Feasibility: Number and Percentage of Participants Who Had Their Pharmacogenetic Tests Returned Prior to Initial Dose — 130; 95 Participants
Phase 1 N=72 Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
Dermatitis, Atopic
Primary: Number of Participants Who Experience One or More Adverse Events (AEs) — 13; 6; 30; 9 Participants
N/A N=39 Exercise Training Effects on Cognition and Brain Function in Multiple Sclerosis: Project EXACT
Multiple Sclerosis · Cognitive Impairment
Primary: Cognitive Processing Speed — 43.5; 43.7; 46.5; 49.1 Raw Score — p=.34
N/A N=39 Internet-Behavioral Cough Suppression Therapy
Cough · Chronic Disease
Primary: Leicester Cough Questionnaire — 9.04; 8.86; 12.78; 9.44 Total LCQ Score — p=.014
N/A N=15 ICG Fluorescence Imaging in Lower Extremity Amputation Patients
Trauma Injury
Primary: Total Bone Blood Flow (TBBF)-Post Osteotomy — 4.9 mL/min/100g
N/A N=250 A Mind-Body Intervention for Hot Flash Management
Hot Flashes · Postmenopausal Symptoms · Breast Cancer
Primary: Hot Flash Daily Diary — 88.7; 94.6; 41.3; 55.9 Hot Flash Score
Phase 2 N=20 Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes
Type 1 Diabetes
Primary: Change in C-peptide Measurement as Reflection of Insulin Secretion at 6 Months — -0.07; -0.07 nmol/L*120 min
Phase 1 N=70 Inflammatory Markers in Trauma Patient Outcomes
Polytrauma
Primary: Length of Hospital Stay — 7; 8 days — p==0.275
Phase 4 N=54 Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
Non-verbal Learning Disorder · Autism Spectrum Disorder · Autism
Primary: Mean Change in the Parent-Young Mania Rating Scale (P-YMRS) Score — 0.0; -2.6 Units on a Scale
Early Phase 1 N=16 A Novel Approach for Brain Stimulation in Severe Stroke
Stroke
Primary: Change in Upper Extremity Fugyl-Meyer Score (UEFM) — 2.625; 2.625 change score from baseline to post-test
N/A N=2,558 Patient Centered Enhancements in School Behavioral Health
Mental Health
Primary: Change in Emotional/Behavioral Functioning of Students Receiving Services — 9.03; 9.21; 8.86; 8.94 score on a scale
Phase 3 N=145 Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Muscular Atrophy, Spinal
Primary: Part B Infantile-onset SMA: Change From Baseline in CHOP-INTEND Total Score for 50/28mg Nusinersen Versus CS3B Matched Sham Control Group — 42.9; 16.9 score on scale…
N/A N=39 An HIV Status-neutral Microeconomic Intervention
Feasibility Studies
Primary: Acceptability Quantitative — 3.9; 3.8 score on a scale — p=<0.05